共 33 条
- [21] Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical TrialsCLINICAL PHARMACOKINETICS, 2023, 62 (03) : 493 - 504Ji, YanYartsev, VitalyQuinlan, MichelleSerra, PaoloWang, YingboChakraborty, AbhijitMiller, Michelle
- [22] Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)George, Daniel J.Hessel, ColinHalabi, SusanSanford, Ben L.Michaelson, M. DrorHahn, Olwen MaryWalsh, Meghara K.Olencki, ThomasPicus, JoelSmall, Eric JayDakhil, Shaker R.Feldman, Darren R.Mangeshkar, MilanScheffold, ChristianMorris, Michael J.Choueiri, Toni K.
- [23] Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims DataJOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (06): : 525 - +Vogelzang, Nicholas J.Pal, Sumanta K.Ghate, Sameer R.Li, NanxinSwallow, ElysePeeples, MirandaZichlin, Miriam L.Meiselbach, Mark K.Perez, Jose RicardoAgarwal, Neeraj
- [24] Real-world economic outcomes among patients (pts) who initiated sunitinib or pazopanib as first targeted therapy (TT) for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)Vogelzang, Nicholas J.Pal, Sumanta K.Ghate, SameerLi, NanxinSwallow, ElysePeeples, Miranda
- [25] Lenvatinib plus Pembrolizumab as first-line treatment in patients with advanced renal cell carcinoma (aRCC) - real world data from a retrospective multi- center analysisONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 88 - 88Stelmach, RamonaSchlack, KatrinMuhle, ClemensDarr, ChristopherNeuberger, StephanieReichert, MathiasRehlinghaus, MarcFlegar, LukaZengerling, FriedemannCasuscelli, JozefinaCox, AlexanderNestler, TimEgenolf, TimoBrehmer, BernhardVallet, SoniaIvanyi, PhilippNeuberger, ManuelPaffenholz, PiaGrunwald, ViktorZschabitz, Stefanie
- [26] Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Atkins, Michael B.Choueiri, Toni K.Hodi, F. StephenThompson, John A.Hwu, Wen-JenMcDermott, David F.Brookes, MelissaTosolini, AlessandraEbbinghaus, ScotYang, ZijiangGause, Christine K.Perini, Rodolfo F.Ribas, Antoni
- [28] Long-term safety of sorafenib (SOR) for the treatment (tx) of advanced clear-cell renal-cell carcinoma (RCC): Data analysis from patients (pts) treated for over 1 year in the phase III TARGET studyJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Hutson, T. E.Bellmunt, J.Porta, C.Staehler, M.Szczylik, C.Nadel, A.Anderson, S.Bukowski, R. M.Eisen, T.Escudier, B.
- [29] Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)ANNALS OF ONCOLOGY, 2019, 30Albiges, L.Rini, B. I.Haanen, J. B. A. G.Motzer, R. J.Kollmannsberger, C. K.Negrier, S.Nole, F.Bedke, J.Bilen, M. A.Nathan, P.Tomita, Y.Huang, B.Ching, K. A.Chudnovsky, A.Robbins, P. B.di Pietro, A.Thomaidou, D.Choueiri, T. K.
- [30] Maintenance of Clinical Efficacy After Dose Reduction of Ixabepilone Plus Capecitabine in Patients With Anthracycline- and Taxane-Resistant Metastatic Breast Cancer: A Retrospective Analysis of Pooled Data From 2 Phase III Randomized Clinical TrialsCLINICAL BREAST CANCER, 2012, 12 (04) : 240 - 246Valero, VicenteVrdoljak, EduardXu, BingheThomas, EvaGomez, HenryManikhas, AlexeyMedina, CarlosLi, Rubi KhawRo, JungsilBosserman, LindaVahdat, LindaMukhopadhyay, PralayOpatt, DianeSparano, Joseph A.